Toric IOLs reduce astigmatism more than PCRIs

Article

Both toric IOLs and peripheral corneal relaxing incisions (PCRIs) reduce astigmatism, but toric IOLs do so to a greater extent as well as being more predictable, according to results of a recently published study.

Both toric IOLs and peripheral corneal relaxing incisions (PCRIs) reduce astigmatism, but toric IOLs do so to a greater extent as well as being more predictable, according to results of a study recently published in the Journal of Cataract & Refractive Surgery.

For this prospective masked bilateral randomized study, researchers from Moorfields Eye Hospital NHS Foundation Trust, London, enrolled 30 patients (60 eyes) with a preoperative corneal astigmatism of 1.0 to 2.5 D. All patients received a toric IOL in one eye and nontoric IOL plus PCRI in the other eye. Postoperative follow-up was done at 1 hour, 1 month and 6 months to measure uncorrected distance visual acuity, corrected distance visual acuity, autorefraction and subjective refraction. The IOL axis was assessed with retroillumination photos.

Researchers found a statistically significant difference in the mean astigmatism vector reduction in the toric IOL group compared with the PCRI group (1.74 D vs 1.27 D, respectively; P = 0.042). Mean absolute rotation of the toric IOL was 2.5 degrees (maximum 6.3 degrees) in the first 6 months postoperatively. Astigmatism increased in the PCRI group between the 1-month and the 6-month follow-up (mean: 0.38 D; maximum: 1.00 D; P

To view the abstract of this study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.